CLINICALLY PROVEN

10 years of research and several peer-reviewed and published clinical studies demonstrates that the Minoxidil Response Test was able to identify people that needed a hair Sulfotransferase Enzyme Booster.

Clinical Studies:

Goren A, Shapiro J, Roberts J, et al. Clinical utility and validity of minoxidil response testing in androgenetic alopecia. Dermatol Ther. 2015;28(1):13-16. doi:10.1111/dth.12164

 

 

Roberts J, Desai N, McCoy J, Goren A. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia. Dermatol Ther. 2014;27(4):252-254. doi:10.1111/dth.12130

 

 

Goren A, Castano JA, McCoy J, Bermudez F, Lotti T. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatol Ther. 2014;27(3):171-173. doi:10.1111/dth.12111

 

 

McCoy J, Goren A, Naccarato T, et al. Identification of the sulfotransferase iso-enzyme primarily responsible for the bio-activation of topical minoxidil. J Biol Regul Homeost Agents. 2019;33(3):817-819.

 

 

Ramos PM, Goren A, Sinclair R, Miot HA. Oral minoxidil bio-activation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern hair loss. J Eur Acad Dermatol Venereol. 2020;34(1):e40-e41. doi:10.1111/jdv.15891

 

 

Ramos PM, Sinclair R, Miot HA, Goren A. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil treatment in Brazilian female pattern hair loss patients. Dermatol Ther. 2020;33(1):e13195. doi:10.1111/dth.13195

 

 

Ramos PM, Gohad P, McCoy J, Wambier C, Goren A. Minoxidil Sulfotransferase Enzyme (SULT1A1) genetic variants predicts response to oral minoxidil treatment for female pattern hair loss [published online ahead of print, 2020 Jun 21]. J Eur Acad Dermatol Venereol. 2020;10.1111/jdv.16765. doi:10.1111/jdv.16765